Avid Bioservices Inc (CDMO)

[sunstar]

PPHM doesn’t need to run phase2 or 3s at this juncture It will be Durvalumab plus Bavituximab run in multiple phase1s against particular cancer indications. They’re quick and cost effective.

The multiple phase1 trial strategy is to demonstrate the ‘Brekken Effect’, the 200% to 300% increased response rates that Dr. Rolf Brekken described after he combined anti-PS MAbs with downstream immunotherapies, like anti-PD-1 and anti-PD-L1...Durvalumab.

As soon as patients start showing substantially increased response rates in the small relatively rapid immunotherapy combination trials, FDA can award Breakthrough Designation, BTD, for the immunotherapy combination, and it’s game on for acquisition of PPHM.

Safety and doubling to tripling patient response rates will seal a deal.

IMO

sunstar